平良 祐介 (タイラ ユウスケ)

TAIRA Yusuke

写真a

科研費研究者番号

00889412

所属学会・委員会 【 表示 / 非表示

  •  
     
     
     

    日本癌治療学会

  •  
     
     
     

    日本婦人科腫瘍学会

  •  
     
     
     

    日本女性医学会

研究分野 【 表示 / 非表示

  • ライフサイエンス / 産婦人科学

論文 【 表示 / 非表示

  • A high-risk gestational trophoblastic neoplasia derived from a complete hydatidiform mole with coexisting fetus identified by short tandem repeats analysis: A case report.

    Taira Y, Shimoji Y, Nakasone T, Arakaki Y, Nakamoto T, Kinjo T, Kudaka W, Mekaru K, Aoki Y

    Case reports in women's health ( Case Reports in Women's Health )  31   e00336   2021年07月 [ 査読有り ]

    掲載種別: 研究論文(その他学術会議資料等)

     概要を見る

    A complete hydatidiform mole coexisting with a fetus (CHMCF) is a rare form of twin pregnancy. High-risk gestational trophoblastic neoplasia (GTN) can occur after a CHMCF pregnancy, although the frequency is low. In cases of GTN, the clinical diagnosis and that based on the International Federation of Gynecology and Obstetrics (FIGO) scoring system can differ. This case report concerns a patient with a choriocarcinoma that was initially diagnosed and treated as a low-risk stage III GTN following a live birth from a CHMCF pregnancy. We used short tandem repeat (STR) analysis to identify the causative pregnancy as the patient's earlier complete hydatidiform mole. Clinicians should anticipate a high-risk GTN when treating persistent trophoblastic disease (PTD) in patients with a non-typical course.

  • A case of nasal septal perforation caused by bevacizumab for advanced cervical cancer.

    Taira Y, Shimoji Y, Nakasone T, Arakaki Y, Nakamoto T, Kudaka W, Aoki Y

    The journal of obstetrics and gynaecology research ( Journal of Obstetrics and Gynaecology Research )  47 ( 2 ) 833 - 837   2021年02月 [ 査読有り ]

    掲載種別: 研究論文(その他学術会議資料等)

     概要を見る

    Nasal septal perforation caused by bevacizumab is rarely reported in other cancers such as ovarian cancer and breast cancer, but it has not been reported in cervical cancer. A 48-year-old woman with a medical history of chronic allergic rhinitis was diagnosed stage 4B (T2bN1M0) cervical cancer and paclitaxel and carboplatin along with bevacizumab (triweekly) were administered. After eight courses of chemotherapy, nasal septal perforation was noted. The possibility of nasal septal perforation by bevacizumab was considered by excluding other causes. We report the first case of nasal septal perforation caused by bevacizumab for advanced cervical cancer.

  • Usefulness of separately evaluating lymphatic and venous vessel invasion in cervical adenocarcinoma

    Yusuke Taira, Yuko Shimoji, Tadaharu Nakasone, Yoshihisa Arakaki, Tomoko Nakamoto, Takuma Ooyama, Wataru Kudaka, Itomi Kaneshima, Kumiko Nishihira, Yoichi Aoki

    Ryukyu Medical Journal   39   21 - 28   2020年10月 [ 査読有り ]

    掲載種別: 研究論文(その他学術会議資料等)

  • Relative dose intensity and overall treatment time in older patients with cervical cancer treated with concurrent chemoradiotherapy.

    Nakamura R, Shimoji Y, Nakasone T, Taira Y, Arakaki Y, Nakamoto T, Ooyama T, Kudaka W, Mekaru K, Aoki Y

    Journal of geriatric oncology ( Journal of Geriatric Oncology )  12 ( 2 ) 332 - 334   2020年09月 [ 査読有り ]

    掲載種別: 研究論文(学術雑誌)

  • Long-term Outcomes of Cervical Adenocarcinoma Treated With Concurrent Chemoradiotherapy Using Paclitaxel and Cisplatin.

    Arakaki Y, Ariga T, Heianna J, Shimoji Y, Nakasone T, Taira Y, Nakamoto T, Ooyama T, Kudaka W, Kaneshima I, Nishihira K, Mekaru K, Aoki Y

    In vivo (Athens, Greece) ( In vivo (Athens, Greece) )  34 ( 5 ) 2739 - 2743   2020年09月 [ 査読有り ]

    掲載種別: 研究論文(学術雑誌)

     概要を見る

    © 2020 International Institute of Anticancer Research. All rights reserved. Background/Aim: We retrospectively analyzed the locally advanced adenocarcinoma (AC)/adenosquamous carcinoma (ASC) of the uterine cervix treated with concurrent chemoradiotherapy using cisplatin plus paclitaxel (TP-CCRT). Patients and Methods: Thirty patients with stage IB-IVA AC/ASC were treated with whole pelvis external beam radiotherapy. A high-dose-rate intracavitary brachytherapy was delivered once per week at a fractional dose of 6 Gy. For TP-CCRT, the patients received cisplatin and paclitaxel. Results: A complete response was achieved in 17 patients (77.3%) in the TP-CCRT group and 4 patients (50.0%) in the P-CCRT group. The 5-year OS rate in the TPCCRT and P-CCRT groups was 74.2% and 25.0% (p=0.0094), the central DFS rate was 58.0% and 12.5% (p=0.0267), and the distant DFS rate was 63.6% and 12.5% (p=0.0042), respectively. Conclusion: TP-CCRT achieves a considerably better disease control for AC of the cervix, leading to a better OS.

全件表示 >>

SDGs 【 表示 / 非表示

  • 婦人科腫瘍